ArticleBlood neoplasia2026

Real-world outcomes of mosunetuzumab use in relapsed/refractory indolent lymphomas: a CUBIC consortium analysis.

Andrew P Jallouk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.